Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

pulmonary damage

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (6) Akt (2) AP-1 (1) Apoptosis (3) Bacterial (1) Caspase (2) Cathepsin (1) Cyclophilin (1) Cytochrome P450 (2) E1/E2/E3 Enzyme (1) EGFR (1) Influenza Virus (2) Interleukin Related (2) LPL Receptor (1) MDM-2/p53 (1) MMP (1) NADPH Oxidase (1) NF-κB (3) NO Synthase (1) p38 MAPK (2) Phosphodiesterase (PDE) (3) Phospholipase (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (3) Reference Standards (3) SARS-CoV (1) TNF Receptor (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (11) Cardiovascular Disease (7) Endocrinology (5) Infection (4) Inflammation/Immunology (13) Neurological Disease (2)

By Targets:

Adrenergic Receptor (6)

Akt (2)

AP-1 (1)

Apoptosis (3)

Bacterial (1)

Caspase (2)

Cathepsin (1)

Cyclophilin (1)

Cytochrome P450 (2)

E1/E2/E3 Enzyme (1)

EGFR (1)

Influenza Virus (2)

Interleukin Related (2)

LPL Receptor (1)

MDM-2/p53 (1)

MMP (1)

NADPH Oxidase (1)

NF-κB (3)

NO Synthase (1)

p38 MAPK (2)

Phosphodiesterase (PDE) (3)

Phospholipase (1)

Pyroptosis (2)

Reactive Oxygen Species (ROS) (3)

Reference Standards (3)

SARS-CoV (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (2)

By Research Areas:

Cancer (11)

Cardiovascular Disease (7)

Endocrinology (5)

Infection (4)

Inflammation/Immunology (13)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99673

Itepekimab 1 Publications Verification REGN-3500; SAR-440340	Interleukin Related NF-κB	Inflammation/Immunology
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .

HY-14299

Indacaterol 5 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .

HY-N7922

Urolithin M5 1 Publications Verification Decarboxyellagic acid	Influenza Virus p38 MAPK EGFR Akt Reactive Oxygen Species (ROS) Apoptosis	Infection Neurological Disease
Urolithin M5 (Decarboxyellagic acid) is an orally active influenza virus neuraminidase inhibitor and neuroprotective agent, with IC₅₀ values of 174.8 μM (HK68), 191.5 μM (pdm09), 243.2 μM (WSN) and 257.1 μM (PR8) against four influenza virus neuraminidases, respectively. Urolithin M5 inhibits viral neuraminidase activity, thereby blocking influenza virus replication (including oseltamivir (HY-13317)-resistant strains), protecting infected mammals from death and improving pulmonary edema. Urolithin M5 forms a hydrogen-bond stabilized complex with IGF1R, and binds to MAPK14, AKT1, NFKB1 and EGFR. Urolithin M5 reduces reactive oxygen species production, inhibits neuronal apoptosis, restores mitochondrial transmembrane potential, and promotes neurite outgrowth of damaged neuronal cells. Urolithin M5 can be used in research related to influenza virus infection and Alzheimer's disease .

HY-P99583

Suvratoxumab MEDI4893	Bacterial	Infection Inflammation/Immunology
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .

HY-14299A

Indacaterol maleate 5 Publications Verification QAB149	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .

HY-19393

SCH 351591	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology Cancer
SCH 351591 is a highly selective, orally active PDE4 inhibitor, with IC₅₀ values of 58 nM and 153 nM in humans and rats, respectively. SCH 351591 effectively inhibits pathological processes such as cytokine production, eosinophilia, airway hyperresponsiveness and bronchospasm. SCH 351591 also induces microvascular injury, activates mast cells and endothelial cells, and causes increases in serum histamine and various inflammatory factors, leading to early vascular damage. SCH 351591 has been widely used in studies related to asthma, chronic obstructive pulmonary disease and drug-induced vascular injury .

HY-P10939A

Ac-DMLD-CMK TFA	Caspase Pyroptosis	Inflammation/Immunology Cancer
Ac-DMLD-CMK TFA is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DMLD-CMK TFA binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DMLD-CMK TFA alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .

HY-14299AR

Indacaterol maleate (Standard) QAB149 (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .

HY-P10939

Ac-DMLD-CMK	Caspase Pyroptosis	Inflammation/Immunology Cancer
Ac-DmLD-CMK is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DmLD-CMK binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DmLD-CMK alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .

HY-14299R

Indacaterol (Standard)	Reference Standards Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .

HY-124072

HL001	Cyclophilin LPL Receptor MDM-2/p53 Apoptosis Reactive Oxygen Species (ROS)	Cancer
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis .

HY-N9508

Perilla ketone	Cytochrome P450	Inflammation/Immunology
Perilla ketone is a naturally occurring xenobiotic compound. Perilla ketone is activated by pulmonary P450 cytochrome enzymes in the lung, resulting in severe pulmonary damage and development of diffuse pulmonary edema .

HY-171804

Linvemastat FP-020	MMP	Inflammation/Immunology
Linvemastat (Compound FC-4) is an orally active MMP-12 inhibitor (IC₅₀: < 10  nM) with high selectivity of MMP-1, -2, -3, -7, -9, -10 and -14. Linvemastat significantly attenuates lung fibrosis in Bleomycin (HY-108345) induced unilateral lung fibrosis mice model and potently reduces kidney damage, interstitial inflammation or fibrosis in kidney fibrosis model of unilateral ureteral occlusion. Linvemastat can be used for inflammatory diseases research, such as idiopathie pulmonary fibrosis (IPF), inflammatory bowel disease (IBD) and asthma .

HY-136271

MJ33	Phospholipase NADPH Oxidase p38 MAPK Akt NF-κB AP-1 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Cancer
MJ-33 is a competitive phospholipase A₂ (PLA₂) inhibitor with an IC₅₀ of 0.3 μM. MJ-33 inhibits the activation of NOX2 by blocking the PLA₂ activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA₂ (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA₂ (pH 8.5). MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R). MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer .

HY-N9508R

Perilla ketone (Standard)	Cytochrome P450 Reference Standards	Inflammation/Immunology
Perilla ketone is a naturally occurring xenobiotic compound. Perilla ketone is activated by pulmonary P450 cytochrome enzymes in the lung, resulting in severe pulmonary damage and development of diffuse pulmonary edema .

HY-P10718

IMG-2005	Toll-like Receptor (TLR)	Inflammation/Immunology
IMG-2005 is a TLR signaling pathway inhibitor. IMG-2005 mimics the Toll/interleukin-1 receptor (TIR) domain of MyD88, thereby preventing its homodimerization, which causes damage to tracheal epithelial cells and triggers pulmonary immune diseases .

HY-14299D

Indacaterol acetate	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol acetate is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol acetate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol acetate can also be used in cardiovascular disease research .

HY-14299C

Indacaterol xinafoate	Adrenergic Receptor	Inflammation/Immunology
Indacaterol xinafoate is an orally active long-acting β2-adrenergic agonist (LABA) with bronchodilatory effect. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol xinafoate can be utilized in asthma research .

HY-144743

ATX inhibitor 12	Phosphodiesterase (PDE)	Others
ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC₅₀ of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .

HY-181646

PDE4-IN-34	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4-IN-34 is a phosphodiesterase 4 (PDE4) inhibitor, with IC₅₀ values of 19 pM and 14 pM against PDE4B1 and PDE4D2, respectively. PDE4-IN-34 shows weak inhibitory activity against PDE8A1, with an IC₅₀ value of 4.092 μM, and exhibits significant selectivity over other subtypes (IC₅₀ > 10 μM). PDE4-IN-34 improves pulmonary function, reduces inflammatory responses and alleviates lung tissue damage in a rat model induced by cigarette smoke combined with LPS (HY-D1056). PDE4-IN-34 can be used for research related to chronic obstructive pulmonary disease .

HY-183313

IAV-IN-5	Influenza Virus Apoptosis NF-κB Interleukin Related NO Synthase Toll-like Receptor (TLR)	Infection
IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection .

HY-170515A

(E),(Z)-RNF5 agonist 1	E1/E2/E3 Enzyme SARS-CoV	Infection Neurological Disease Cancer
(E),(Z)-RNF5 agonist 1 (Compound Analog-1) is a RNF5 agonist that can enhance the ubiquitination and degradation of SARS-CoV-2 E protein by RNF5. (E),(Z)-RNF5 agonist 1 effectively inhibits the replication of SARS-CoV-2 and significantly alleviates pulmonary pathological damage and systemic inflammatory response in mouse infection models. (E),(Z)-RNF5 agonist 1 has a strong cytotoxic effect on neuroblastoma and melanoma. (E),(Z)-RNF5 agonist 1 can be used for research on anti-cancer and anti-viral purposes .

HY-181741

PI3K-001	Cathepsin	Inflammation/Immunology
PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis .

Cat. No.	Product Name

HY-L114

Anti-inflammatory Traditional Chinese Medicine Active Compound Library	1,535 compounds
Inflammation promotes physiological and pathological processes by the activation of the immune system, local vascular system, and various cells within the damaged tissue. Accumulating epidemiological and clinical evidence shows that chronic inflammation is causally linked to various human diseases, including cerebrovascular, cardiovascular, joint, cutaneous, pulmonary, blood, liver, and intestinal diseases as well as diabetes. Various natural products from Traditional Chinese Medicine (TCM) have been shown to safely suppress proinflammatory pathways and control inflammation-associated disease. MCE designs a unique collection of 1,535 Traditional Chinese Medicine active compounds with anti-inflammatory activity, which are derived from Coptis chinensis, Radix isatidis, Flos Lonicerae, Forsythia suspensa, etc. MCE Anti-inflammatory Traditional Chinese Medicine Active Compound Library is a useful tool for discovery anti-inflammatory drugs from TCM.

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

1,535 compounds

Inflammation promotes physiological and pathological processes by the activation of the immune system, local vascular system, and various cells within the damaged tissue. Accumulating epidemiological and clinical evidence shows that chronic inflammation is causally linked to various human diseases, including cerebrovascular, cardiovascular, joint, cutaneous, pulmonary, blood, liver, and intestinal diseases as well as diabetes.

Various natural products from Traditional Chinese Medicine (TCM) have been shown to safely suppress proinflammatory pathways and control inflammation-associated disease. MCE designs a unique collection of 1,535 Traditional Chinese Medicine active compounds with anti-inflammatory activity, which are derived from Coptis chinensis, Radix isatidis, Flos Lonicerae, Forsythia suspensa, etc. MCE Anti-inflammatory Traditional Chinese Medicine Active Compound Library is a useful tool for discovery anti-inflammatory drugs from TCM.

Cat. No.	Product Name	Target	Research Area